Efficacy of Ezetimibe/Simvastatin 10/20 mg and MK0524A (1-2 g/Day) in Mixed Hyperlipidemia and Two or More Risk Factors
Status:
Withdrawn
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
To measure the percentage of patients who achieve all the treatment lipid goals being treated
with ezetimibe/simvastatin 10/20 with or without MK0524A (1-2 g/day).
Phase:
Phase 4
Details
Lead Sponsor:
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Ezetimibe Ezetimibe, Simvastatin Drug Combination Simvastatin